Physician profile
Brian D Proctor
NPI 1649276833
$6,577.68
in general payments reported to CMS, 2019-2025
28 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $779 · 2021: $1,073 · 2022: $713 · 2023: $649 · 2024: $1,436 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,556.94 | 2019-2025 | Centurion, Clareon, Rocklatan |
| Abbvie INC. | $696.92 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $419.91 | 2022-2025 | Acthar |
| Allergan, INC. | $365.30 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $354.43 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $227.02 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Amgen INC. | $205.31 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $170.59 | 2019-2022 | |
| Horizon Therapeutics Plc | $146.53 | 2022-2023 | Tepezza |
| Rxsight INC | $140.22 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Eyepoint US, INC. | $136.59 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $130.84 | 2024 | Atlas 500, Mel 90, Iolmaster 700 |
| Glaukos Corporation | $128.18 | 2019-2025 | Idose, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $113.00 | 2019-2021 | |
| Harrow Eye, LLC | $112.07 | 2024-2025 | Vevye |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $95.85 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $77.59 | 2019 | |
| Sight Sciences, INC. | $74.32 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $74.27 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $60.10 | 2022-2024 | Dextenza |
| Dompe US, INC. | $48.07 | 2021-2025 | Oxervate |
| Astellas Pharma US INC | $47.66 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $44.16 | 2024 | Tyrvaya |
| Thea Pharma INC. | $43.39 | 2024 | Iyuzeh |
| Ivantis, INC | $33.70 | 2021 | |
| Quidel Corporation | $33.24 | 2022 | |
| Merz North America, INC. | $21.16 | 2019 | |
| Shire North American Group INC | $20.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.